Literature DB >> 7963737

Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS.

P Gallay1, C Barras, P S Tobias, T Calandra, M P Glauser, D Heumann.   

Abstract

Lipopolysaccharide (LPS)-binding protein (LBP) and CD14 represent key elements in monocyte activation by LPS. The mean concentration of LBP was 18.1 microgram/mL in normal serum and 40-60 micrograms/mL in serum of patients with septic shock, independent of the fact that patients had gram-negative or other infections. Ten percent normal serum presented large concentrations of LPS (in the microgram range) to monocytes. Only when diluted 1:100 was LBP in plasma a limiting factor for monocyte activation, as measured by tumor necrosis factor (TNF) release. When LBP was depleted from serum with anti-LBP antibodies, the resulting serum did not support TNF release of monocytes upon LPS challenge. In conclusion, monocyte activation resulting in TNF secretion was related to LBP, which is abundantly present in normal serum, and elevated two to three times in patients with septic shock.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963737     DOI: 10.1093/infdis/170.5.1319

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.

Authors:  R Salomão; O Rigato; A C Pignatari; M A Freudenberg; C Galanos
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 3.553

2.  Increased levels of lipopolysaccharide binding protein in plasma in children with kawasaki disease.

Authors:  Seiichiro Takeshita; Hiroshi Tsujimoto; Hiroko Kawase; Youichi Kawamura; Isao Sekine
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

3.  Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis.

Authors:  Nicolas T Schwarz; Donna Beer-Stolz; Richard L Simmons; Anthony J Bauer
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

4.  Levels of soluble CD14 and lipopolysaccharide-binding protein in human basal tears.

Authors:  Ken Fukuda; Naoki Kumagai; Teruo Nishida
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

5.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells.

Authors:  T Fujii; J Kadota; T Morikawa; Y Matsubara; K Kawakami; K Iida; R Shirai; H Taniguchi; M Kaseda; S Kawamoto; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.

Authors:  N Lamping; R Dettmer; N W Schröder; D Pfeil; W Hallatschek; R Burger; R R Schumann
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

8.  The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome.

Authors:  A Myc; J Buck; J Gonin; B Reynolds; U Hammerling; D Emanuel
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis.

Authors:  Jesús Villar; Lina Pérez-Méndez; Elena Espinosa; Carlos Flores; Jesús Blanco; Arturo Muriel; Santiago Basaldúa; Mercedes Muros; Lluis Blanch; Antonio Artigas; Robert M Kacmarek
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.